Novel Strategy for Three-Dimensional Fragment-Based Lead Discovery

被引:17
|
作者
Yuan, Haoliang [1 ]
Lu, Tao [1 ]
Ran, Ting [1 ]
Liu, Haichun [1 ]
Lu, Shuai [1 ]
Tai, Wenting [1 ]
Leng, Ying [1 ]
Zhang, Weiwei [1 ]
Wang, Jian [1 ]
Chen, Yadong [1 ]
机构
[1] China Pharmaceut Univ, Lab Mol Design & Drug Discovery, Sch Basic Sci, Nanjing 210009, Peoples R China
基金
中国国家自然科学基金;
关键词
DEPENDENT KINASE INHIBITORS; STRUCTURE-GUIDED DESIGN; HIGH-AFFINITY LIGANDS; C-MET INHIBITORS; DRUG DESIGN; CDK2; INHIBITORS; ANILINO PYRIMIDINES; SELECTIVE CLASS; BINDING MODE; POTENT;
D O I
10.1021/ci200003c
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Fragment-based drug design (FBDD) is considered a promising approach in lead discovery. However, for a practical application of this approach, problems remain to be solved. Hence, a novel practical strategy for three-dimensional lead discovery is presented in this work Diverse fragments with spatial positions and orientations retained in separately adjacent regions were generated by deconstructing well-aligned known inhibitors in the same target active site. These three-dimensional fragments retained their original binding modes in the process of new molecule construction by fragment linking and merging. Root-mean-square deviation (rmsd) values were used to evaluate the conformational changes of the component fragments in the final compounds and to identify the potential leads as the main criteria. Furthermore, the successful validation of our strategy is presented on the basis of two relevant tumor targets (CDK2 and c-Met), demonstrating the potential of our strategy to facilitate lead discovery against some drug targets.
引用
收藏
页码:959 / 974
页数:16
相关论文
共 50 条
  • [21] Fragment Shuffling: An Automated Workflow for Three-Dimensional Fragment-Based Ligand Design
    Nisius, Britta
    Rester, Ulrich
    JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2009, 49 (05) : 1211 - 1222
  • [22] Fragment-Based Lead Discovery Strategies in Antimicrobial Drug Discovery
    Konaklieva, Monika I.
    Plotkin, Balbina J.
    ANTIBIOTICS-BASEL, 2023, 12 (02):
  • [23] Discovery of a novel warhead against β-secretase through fragment-based lead generation
    Geschwindner, Stefan
    Olsson, Lise-Lotte
    Albert, Jeffrey S.
    Deinum, Johanna
    Edwards, Philip D.
    de Beer, Tonny
    Folmer, Rutger H. A.
    JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (24) : 5903 - 5911
  • [24] Mapping bioactivity space for fragment-based lead discovery
    Oprea, TI
    Olah, M
    Mracec, M
    Rad, R
    Ostopovici, L
    Bora, A
    Hadaruga, N
    Bologa, CG
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 229 : U157 - U157
  • [25] Thermodynamic profiling for fragment-based lead discovery and optimization
    Ferenczy, Gyorgy G.
    Keseru, Gyorgy M.
    EXPERT OPINION ON DRUG DISCOVERY, 2020, 15 (01) : 117 - 129
  • [26] Current perspectives in fragment-based lead discovery (FBLD)
    Lamoree, Bas
    Hubbard, Roderick E.
    STRUCTURE-BASED DRUG DESIGN: INSIGHTS FROM ACADEMIA AND INDUSTRY, 2017, 61 (05): : 453 - 464
  • [27] Fragment-based lead discovery of a novel Map4k4 inhibitor
    Wang, Lan
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 253
  • [28] Integrated biophysical approach to fragment screening and validation for fragment-based lead discovery
    Silvestre, Hernani Leonardo
    Blundell, Thomas L.
    Abell, Chris
    Ciulli, Alessio
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (32) : 12984 - 12989
  • [29] Capitalizing on Fragment-Based Discovery
    Liszewski, Kathy
    GENETIC ENGINEERING & BIOTECHNOLOGY NEWS, 2009, 29 (08): : 18 - +
  • [30] Fragment-based drug discovery
    Erlanson, DA
    McDowell, RS
    O'Brien, T
    JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (14) : 3463 - 3482